Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sol-Gel Technologies Ltd. (SLGL : NSDQ)

• Company Description    Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $42.14 Daily Weekly Monthly 20 Day Moving Average: 18,044 shares Shares Outstanding: 2.79 (millions) Market Capitalization: $117.39 (millions) Beta: 1.35 52 Week High: $52.26 52 Week Low: $4.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.54% 3.71% 12 Week 6.28% 4.57% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 GOLDA MEIR ST WEIZMANN SCIENCE PARK - NESS ZIONA,L3 7403650 ISR ph: 972-8931-3429 fax: 972-153-523044444 ikoffler@lifesciadvisors.com http://www.sol-gel.com

• General Corporate Information    Officers Moshe Arkin - Executive Chairman of the Board of Directors and i Itzik Yosef - Chief Operating Officer Eyal Ben-Or - Chief Financial Officer Ofer Toledano - Vice President Research and Development Itai Arkin - Director Peer Information Sol-Gel Technologies Ltd. (BGMR) Sol-Gel Technologies Ltd. (BBIO) Sol-Gel Technologies Ltd. (IPAH) Sol-Gel Technologies Ltd. (BRL) Sol-Gel Technologies Ltd. (BHC) Sol-Gel Technologies Ltd. (AKRXQ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-GENERIC DRG Sector: Medical CUSIP: M8694L137 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 2.79 Most Recent Split Date: 5.00 (0.10:1) Beta: 1.35 Market Capitalization: $117.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.84 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.51 Price/Cash Flow: - Price / Sales: 6.19 EPS Growth vs. Year Ago Period: -2,030.00% vs. Previous Quarter: -151.08% Sales Growth vs. Year Ago Period: -92.54% vs. Previous Quarter: -97.68% ROE 12/31/25 - - 09/30/25 - -33.61 06/30/25 - -11.80 ROA 12/31/25 - - 09/30/25 - -26.27 06/30/25 - -9.39 Current Ratio 12/31/25 - - 09/30/25 - 5.15 06/30/25 - 7.32 Quick Ratio 12/31/25 - - 09/30/25 - 5.15 06/30/25 - 7.32 Operating Margin 12/31/25 - - 09/30/25 - -47.37 06/30/25 - -14.25 Net Margin 12/31/25 - - 09/30/25 - -47.37 06/30/25 - -14.25 Pre-Tax Margin 12/31/25 - - 09/30/25 - -47.37 06/30/25 - -14.25 Book Value 12/31/25 - - 09/30/25 - 9.34 06/30/25 - 11.44 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©